Company profile
Bioxytran, Inc.
OTC: BIXT · Healthcare · Biotechnology
#1005 of 1,418 Healthcare companies by revenue27th-percentile growth
EA Score
27DFH 18DQ 32GM 42SS 36
v0.1 · 65/100 weight · provisional
↑ growth stability, listing tenure · ↓ workforce scale, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.1M
Employees
2
as of 2026-08-24
Market cap
$2.1M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$191.1k$191.1k2017
Net income-$2.1M-$2.1M2025
Operating income-$1.8M-$1.8M2025
Total assets$658.6k$658.6k2025
Liabilities$3.2M$3.2M2025
Equity-$2.6M-$2.6M2025
Revenue trend
FY2011 – FY2017 · USD
FY11
FY11
FY12
FY13
FY14
FY15
FY17
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bioxytran, Inc.’s revenue?
Bioxytran, Inc. booked $191.1k in FY2017 revenue, contracting 22% year over year — slower than 73% of Healthcare companies we track, at a -1111.1% net margin.
Peers · Healthcare
Clene Inc.27DWindtree Therapeutics, Inc.——CardioComm Solutions, Inc.25DaTyr Pharma, Inc.36DHemp, Inc——NuGen Medical Devices Inc.24DNeighbors
Middlesex →Key facts
CEODavid Platt
SectorHealthcare
IndustryBiotechnology
HeadquartersNewton, MA
ExchangeOTC: BIXT
Employees2
IPO date2010-01-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.